REporting recommendations for tumour MARKer prognostic studies (REMARK).
about
Preclinical Childhood Sarcoma Models: Drug Efficacy Biomarker Identification and ValidationMicroRNA-21 and the clinical outcomes of various carcinomas: a systematic review and meta-analysisPrognostic significance of c-Met in breast cancer: a meta-analysis of 6010 casesReporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration.MicroRNA profile of poorly differentiated thyroid carcinomas: new diagnostic and prognostic insights.Relation of completeness of reporting of health research to journals' endorsement of reporting guidelines: systematic reviewNeuropilin-1 is upregulated in the adaptive response of prostate tumors to androgen-targeted therapies and is prognostic of metastatic progression and patient mortality.TIMP-1 and responsiveness to gemcitabine in advanced breast cancer; results from a randomized phase III trial from the Danish breast cancer cooperative group.Increased androgen receptor expression in serous carcinoma of the ovary is associated with an improved survival.Circulating tumor cells in non-metastatic triple-negative breast cancer.Therapeutic targeting of integrin αvβ6 in breast cancer.Bax expression measured by AQUAnalysis is an independent prognostic marker in oral squamous cell carcinoma.Low ERK phosphorylation in cancer-associated fibroblasts is associated with tamoxifen resistance in pre-menopausal breast cancer.Timing of autologous stem cell transplantation from last chemotherapy affects lymphocyte collection and survival in non-Hodgkin lymphomaGene aberrations of RRM1 and RRM2B and outcome of advanced breast cancer after treatment with docetaxel with or without gemcitabine.The impact of IGF-1R expression on the outcomes of patients with breast cancer: a meta-analysis.Phase II study of preoperative bevacizumab, capecitabine and radiotherapy for resectable locally-advanced rectal cancer.Statistical association of basal cell keratins with metastasis-inducing proteins in a prognostically unfavorable group of sporadic breast cancers.Low calpain-9 is associated with adverse disease-specific survival following endocrine therapy in breast cancermiR-21 and miR-155 are associated with mitotic activity and lesion depth of borderline melanocytic lesions.Circulating miR-200c and miR-141 and outcomes in patients with breast cancer.MicroRNA-93 activates c-Met/PI3K/Akt pathway activity in hepatocellular carcinoma by directly inhibiting PTEN and CDKN1AC6ORF97-ESR1 breast cancer susceptibility locus: influence on progression and survival in breast cancer patients.Multiparameter analysis of homogeneously R-CHOP-treated diffuse large B cell lymphomas identifies CD5 and FOXP1 as relevant prognostic biomarkers: report of the prospective SAKK 38/07 study.CYP1A2--a novel genetic marker for early aromatase inhibitor response in the treatment of breast cancer patientsAlterations of TP53 are associated with a poor outcome for patients with hepatocellular carcinoma: evidence from a systematic review and meta-analysis.Outcomes Definitions and Statistical Tests in Oncology Studies: A Systematic Review of the Reporting ConsistencyEnhanced stability of microRNA expression facilitates classification of FFPE tumour samples exhibiting near total mRNA degradation.Prognostic significance of SATB1 in gastrointestinal cancer: a meta-analysis and literature reviewThe Informatics Challenges Facing Biobanks: A Perspective from a United Kingdom Biobanking Network.Publication of tumor marker research results: the necessity for complete and transparent reporting.PKCα Attenuates Jagged-1-Mediated Notch Signaling in ErbB-2-Positive Breast Cancer to Reverse Trastuzumab Resistance.Germline polymorphisms in genes involved in the Hippo pathway as recurrence biomarkers in stages II/III colon cancer.Colorectal cancer epigenetics: the role of environmental factors and the search for molecular biomarkers.Personalized medicine and oncology practice guidelines: a case study of contemporary biomarkers in colorectal cancer.Biomarker use in colorectal cancer therapy.Independent Replication of Published Germline Polymorphisms Associated with Urinary Bladder Cancer Prognosis and Treatment ResponseImmunogenic Subtypes of Breast Cancer Delineated by Gene Classifiers of Immune Responsiveness.Retinoic acid receptor alpha is associated with tamoxifen resistance in breast cancerFocal adhesion kinase: predictor of tumour response and risk factor for recurrence after neoadjuvant chemoradiation in rectal cancer.
P2860
Q26784048-FFD96DB0-EB89-4C9B-A12F-1B611E77B162Q26851333-68A3CF8C-2CB9-4566-80D9-A09529AC8A19Q28087523-BC5E0BA7-F969-47C2-BE92-F0D2EEF2AA0DQ30514241-473501C7-24D6-4198-BF8F-56C87E905EBAQ33568629-4054000F-E17E-412C-BB4D-D980C6058D6EQ33804561-C4330ED5-A41E-4FA7-A040-0C48D5B3A7C4Q33835918-C93DA313-D821-4A30-BED6-0C457C3AAE7AQ33880656-DA4AB388-4953-45CD-8A3D-C46DB8EB91E3Q33986711-6DF6C7DD-03BF-4B4F-8D94-C5019DCF43C8Q34111867-72E6915F-5F9F-4206-8436-950589375E9BQ34120685-6FF58887-CE5B-4B4B-BC70-604C70055F7FQ34361458-6468A167-C1CE-430C-BDD8-6A1780212030Q34429766-C3C0E8FE-A66D-4CA7-976A-23D947AC0627Q34652062-1277A7DC-BC88-4B35-91CA-0924D35DD7EFQ35038441-655F78CF-483C-482B-A1D4-8FB23B4559ADQ35063782-A4A8CF26-6E06-4565-905C-A55D62986189Q35128016-91BF9AF9-FE27-4A8A-A1AA-4A8AE666EC49Q35168065-A7FD98ED-CFE8-4561-9335-7C79D9FD9DD9Q35190290-32037D1A-D1FF-4154-AB59-4A309D90C6D1Q35262736-B02AD354-A042-40DB-B40A-247D4EB5BC58Q35518887-B3E10E4C-7A04-41D7-81B7-C5BE28878594Q35550210-1472B415-D659-4FF8-85B6-BF3965BEA4F1Q35722184-77CFE806-2EF3-46B1-B640-BCBABF7377F3Q35755485-EC19E837-D145-4925-80B1-56C67393D0F0Q35974459-90A65B23-3E75-4369-B048-F1DB217C2418Q36092123-BF183ADF-A6CB-469E-853A-E01BA2061031Q36157554-142A049F-2348-451D-829D-4F5492B5EBD5Q36166783-D2EDFE83-1051-4221-8BFF-A05EA8C7CE9DQ36353433-F75384ED-7D70-428F-81B3-67F52F4E8D7EQ36362139-4799A9DF-581B-40C1-B68F-551FCEDB3A04Q36417739-ED1AF451-EC71-4485-ABD9-87635FF11F29Q36437097-6542153A-27F5-4A72-953F-3FFB54D9646EQ36689794-311E0F47-6A0F-4DE0-B5F0-D66468496CF5Q36844969-A444CE05-B493-490D-AA97-95B8C6D7B813Q36964450-208842C0-47E6-4EEB-94C8-CBEA305D4C9FQ36968539-49CD8CCE-7F17-4AEB-B840-0F6846743026Q37054113-551AAD89-22FE-4E99-BA1A-FB2AAABD98B1Q37059747-4B183759-C4B5-46B8-AFD2-4994C142ACFEQ37137065-AFE0E0DB-91DE-4592-840D-DACD5F413A80Q37182965-68CE2F88-F1F4-4453-BE30-66234E9DCA30
P2860
REporting recommendations for tumour MARKer prognostic studies (REMARK).
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
REporting recommendations for tumour MARKer prognostic studies (REMARK).
@en
REporting recommendations for tumour MARKer prognostic studies
@nl
type
label
REporting recommendations for tumour MARKer prognostic studies (REMARK).
@en
REporting recommendations for tumour MARKer prognostic studies
@nl
prefLabel
REporting recommendations for tumour MARKer prognostic studies (REMARK).
@en
REporting recommendations for tumour MARKer prognostic studies
@nl
P2093
P1476
REporting recommendations for tumour MARKer prognostic studies (REMARK).
@en
P2093
Gary M Clark
Lisa M McShane
Massimo Gion
Sheila E Taube
Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics
Willi Sauerbrei
P304
P356
10.1016/J.EJCA.2005.03.032
P577
2005-08-01T00:00:00Z